2013 9 1512:00~13:00 2F http:// imazu.org
5 1 68 19 54 127 14 17 100 31 http:// imazu.org
1 55 200X S 201X http:// imazu.org
1 55 http:// imazu.org
1 55 http:// imazu.org
75mg/ 1 9g / 21 mg 70 % 14.7 mg 14.7 ~ 33.6mg 7
65 200X C RFA 201X http:// imazu.org
65 68 p.103 10
1 2.5 g 1.! 2.! 3.! 1~3 : 14, 19, 32, 56, 64, 68, 72, 77, 82, 120, 122, 138 p.180 13
3 55 107 87 ( ) 7 ( 0.5 g ) 7 ( ) 107 ( 1.0 g ) 16
0.5 g 1.5 g/day ph p.179, p.181 17
!!!!!!! 2 http:// imazu.org
126 51 84 14 60 32 100 7 p.54 21
3, 8, 13, 51, 59, 61, 62, 74, 84, 89, 105, 113, 126, 133, 134, 135 p.179, p.181 22
33, 61, 62, 74, 105, 133 p.179 23
Hydroxy-α-Sanshool 6-Shogaol TRP A1 ADM CGRP Hydroxy-α-Sanshool TRP A1 Substance-P Transient Receptor Potential TRP 24
100 99 60 * * 1st 2nd 25
TNF-α IL-1β COX2, IL-β LPS Receptor H2 E2 1.Phospholipid Arachidonic acid COX-2 PGH2, PGG2 2.MAPK cascade Transcription factors (KF-κB, AP-1) COX-2 Berberine Gingerols, Shogaols Wogonin Berberine 26 p.21
100 14,, TRP,,,,,, 27
Yokukansan in the treatment of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis of randomized controlled trials Yuki Matsuda, Taro Kishi*, Hiroto Shibayama and Nakao Iwata Hum. Psychopharmacol Clin Exp 2013; 28: 80 86. Objectives There is currently no meta-analysis of the efficacy and tolerability of Yokukansan in the treatment of behavioral and psycho- logical symptoms of dementia. Method We used information obtained from the PubMed and Cochrane Library databases until October 2012. We conducted a systematic review and meta-analysis of individual patient data from randomized controlled trials comparing Yokukansan with usual care (UC, i.e., con- trols). Standardized mean difference and weighted mean difference were calculated. All studies used the Neuropsychiatric Inventory (NPI) for the evaluation of behavioral and psychological symptoms of dementia. Results Four relevant studies (total n=236) were identified. Yokukansan was superior to UC in the reduction of total NPI scores (p = 0.0009, weighted mean difference =7.20, I2 = 0%). In addition, Yokukansan was more efficacious in reducing scores on the NPI sub- scale (delusions, hallucinations, and agitation/aggression) than UC (p < 0.00001 0.0009). Yokukansan treatment also improved activities of daily living scores compared with UC (p = 0.04, standardized mean difference = 0.32, I2 = 0%). Mini-mental state examination scores did not differ between the Yokukansan and UC treatment groups. Yokukansan was not different from UC regarding discontinuation due to any cause. Conclusion Our results suggest that Yokukansan has a beneficial effect on NPI and on ADL scores and that Yokukansan seems to be a well-tolerated treatment. 32
33 Hum. Psychopharmacol Clin Exp 2013; 28: 80 86.
CONCLUSION Our results suggest that Yokukansan has a more beneficial effect on Behavioral and Psychological Symptoms of Dementia (BPSD) and Activites of Daily Living (ADL) scores in patients with dementia than do Usual Care (UC), and this treatment seemed to be well-tolerated. However, double-blind, randomized, controlled clinical trials should be conducted to further explore the utility of Yokukansan in dementia patients with BPSD. Hum. Psychopharmacol Clin Exp 2013; 28: 80 86. 34
(aquaporin;aqp) AQP 13 AQP () AQP4 > AQP1 > AQP5 > AQP3 AQP 0 AQP 1,,,,,,,,,, AQP 2,, AQP 3,,,,,,,, AQP 4,,,,,,,, AQP 5,,,,, AQP 6 AQP 7,,,, AQP 8,,,, AQP 9,,,,, [ ] ( ) ( ) ( )[, ] ( ),,( ) [,, ] ( AQP4 ) [,,,,] [, ] [] [] [ ] AQP 10, AQP 11,,, [] AQP 12, Science of Kampo Medicine Vol.37 No.2 2013
(aquaporin;aqp) AQP4 Control μm/sec 120 90 * p<0.05 60 30 * * 0 AQP4 (n=4) EDTA2 Mn, Co, Cu, Cr Mn Science of Kampo Medicine Vol.35 No.2 2011
(aquaporin;aqp) AQP 13 AQP4 > AQP1 > AQP5 > AQP3 AQP5 > AQP3, AQP4 ERK Science of Kampo Medicine Vol.37 No.2 2013
:., 2006,.,.,,. ( days/4 w ) 11 8 6 Placebo P=0.001 Placebo 11 8 6 Placebo P=0.008 Placebo 3 3 0 0,.,
: 43 3 1.5 1 1 0.5 42
55 201X 6 201X 7 H2 blocker PPI PS / http:// imazu.org 43
PS Performance Status 0 1 250 PS 0 + PS > 0 3 50 4 Osoba D, MacDobald N. Doyle F, et al (eds): Oxford Textbook of Palliative Medicine, 2nd ed. Oxford University Press, 1998 p.42 http:// imazu.org 44
55 P S 0 1 2 3 4 41 48 108 43 32 p.129 http:// imazu.org 45
55 41 48 108 PS 0 N K T p.60, p.76, p.81, p.87, p.100 http:// imazu.org 46
55 43 32 75 75 75 ( ( 71 43 43 41 ( ) ( ) 48 p.129 p.136 p.159 http:// imazu.org 47
1 L- GERD (NERD, ERD) 2 L- FD, PDS, EPS 3 5-HT2cR Ach FD, PDS, EPS 4 GERD; Gastroesophageal reflux dissease NERD; Non-erosive reflux disease ERD; Erosive reflux disease FD; Functional dyspepsia PDS; Postprandial distress syndorome EPS; Epigastric pain syndorome http:// imazu.org
55 43 32 Bristol 7 p.124 p.144 p.159 http:// imazu.org 49
HTTP://WWW.KAMPO-S.JP http:// imazu.org